Cytokine and Growth Factor Activation In Vivo and In Vitro after Spinal Cord Injury

Elisa Garcia1, Jorge Aguilar-Cevallos1, Raul Silva-Garcia2

  • 1Facultad de Ciencias de la Salud, Universidad Anáhuac, 52786 Huixquilucan, MEX, Mexico; Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac, 52786 Huixquilucan, MEX, Mexico.

Insights

Spinal cord injury (SCI) triggers harmful inflammation and cell death. Understanding these complex mechanisms is key to developing treatments for SCI recovery.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathophysiology

Background:

  • Spinal cord injury (SCI) initiates primary and secondary injury phases involving complex molecular mechanisms.
  • Gene upregulation, particularly in inflammation, transcription, and signaling proteins, mediates SCI pathophysiology.
  • Cytokines and growth factors are critical signaling proteins influencing lesion progression and outcomes.

Purpose of the Study:

  • To elucidate the role of signaling proteins, specifically cytokines and growth factors, in the inflammatory cascade following spinal cord injury.
  • To investigate how the balance between pro-inflammatory and anti-inflammatory signaling impacts the secondary injury phase and overall lesion outcome.

Main Methods:

  • Analysis of gene expression patterns related to inflammation and signaling pathways post-SCI.
  • Assessment of cytokine and growth factor profiles in the injured spinal cord environment.
  • Evaluation of the impact of inflammatory phenotypes (Th1 and Th17) on secondary injury mechanisms.

Main Results:

  • Upregulation of genes involved in inflammation, transcription, and signaling proteins observed after SCI.
  • Pro-inflammatory cytokines and growth factors contribute significantly to the secondary injury cascade.
  • Excessive Th1 and Th17 phenotypes promote a pro-inflammatory environment, exacerbating secondary injury.

Conclusions:

  • The balance of pro-inflammatory and anti-inflammatory signaling molecules is crucial for SCI outcomes.
  • Dysregulation of signaling proteins, particularly cytokines, drives neuroinflammation and secondary injury.
  • Targeting inflammatory pathways offers potential therapeutic strategies for mitigating SCI-induced neurodegeneration.